Introduction
============

Thyroid carcinoma is the most common endocrine malignancy worldwide, the incidence of which is increasing. The most common subtype of thyroid carcinoma is papillary carcinoma (PTC), accounting for 80--90% of all cases ([@bib1]). Although this type of cancer has an excellent prognosis, the prognosis significantly worsens when the tumor grows and metastasizes ([@bib2]). For this reason, it is important to understand the characteristics of the tumor at the early stage.

Several epidemiological reports show that higher levels of vitamin D3 are associated with a lower risk of developing cancer ([@bib3]). The active form of vitamin D3, 1,25-dihydroxyvitamin D3 (1,25D) exerts antitumor activity by binding to the vitamin D receptor (*VDR*). The antitumor activities of 1,25D include the inhibition of cancer cell proliferation and angiogenesis, promotion of cell differentiation and apoptosis ([@bib4], [@bib5], [@bib6], [@bib7], [@bib8]).

The *VDR* is a receptor expressed by epithelial cells in both normal and malignant thyroid glands. Human *VDR* gene is located on chromosome 12q13.1 ([@bib9]). In cancer cells, *VDR* expression is a response to 1,25-dihydroxyvitamin D3 (1,25D) by decreasing proliferative activity *in vitro*. Izkhakov and coworkers reported that expression of *VDR* mRNA in malignant thyroid tissues is higher than that in normal thyroid ([@bib2]). They also reported correlations between *VDR* and other genes such as *ECM1* (extracellular matrix protein-1) and *TMPRSS4* (type II transmembrane serine protease-4), which are associated with tumor progression. Positive correlation was also observed between *VDR* and *ECM1*, as well as between *VDR* and *TMPRSS4* ([@bib2]).

Our study was designed to evaluate the correlation between the *VDR* mRNA expression and prognostic factors of PTC using 'The Cancer Genome Atlas' (TCGA) data. TCGA kindly provides multiplatform genomics data such as sequence and read count data from next-generation sequencing, copy-number analysis, methylomics and proteomics data ([@bib10]). Genomic data were also combined with patient-matched clinical data to correlate the molecular findings with clinical characteristics.

Materials and methods
=====================

Data preparation
----------------

We downloaded TCGA thyroid cancer data, including clinical information, somatic mutations and gene expression data derived from RNA sequencing. Pathologic data were re-evaluated using scanned images of the paper-written pathologic documents provided by TCGA-associated hospitals. PTC subtype classification and MACIS scores were referenced from the 2014 TCGA thyroid cancer paper's Supplemental Tables ([@bib10]). The total number of TCGA samples comprised 59 normal tissues and 501 cancer tissues. Total 499 patient samples were assessed after joining the clinical data without missing attributes.

Somatic mutations were provided by two different mutation calling files from the Illumina DNA-sequencing machine. Sequencing experiments were performed by the Baylor College of Medicine, the Broad Institute at MIT and Harvard Genome Sequencing Center. Mutation status of *BRAF*, *RAS* (*NRAS*, *HRAS* and *KRAS*) and *VDR* genes was identified from somatic mutation calling files: identical results in two different calling files were considered as a meaningful mutation.

TCGA gene expression data from RNA sequencing were provided with level 3 RSEM (RNA-Seq by expectation--maximization) counts after upper quartile normalization to maintain the standardization of different platforms or housekeeping genes (<https://wiki.nci.nih.gov/>). RNA sequencing was performed by the University of North Carolina using an Illumina HiSeq RNA Sequencing machine. We analyzed *VDR* gene expression according to tissue type (normal vs cancer) and clinical information. Next, all 20,531 genes were used to assess gene ontology and pathway analysis.

Statistical analysis
--------------------

Paired *t*-test was used to assess the differences in gene expression between 59 paired donor-matched normal and cancer samples, whereas unpaired *t*-test was used to assess the global differences between the 59 normal tissues and 499 cancer tissues. Association between clinical variables and *VDR* gene expression was measured by univariable and multivariable linear regression analysis. To predict cancer recurrence based on *VDR* expression, continuous *VDR* expressions was converted into two binary groups (low *VDR* and high *VDR* group) using tree-based classification analysis with a maximized area under the ROC (receiver-operating characteristic) curve. Binary *VDR* groups were used for univariable and multivariable logistic regression analyses to assess the relationship between *VDR* expression and clinicopathologic variables. Backward selection method was used in both linear and logistic regression for multiple model fitting. Kaplan--Meier estimator with log-rank test was used for survival analysis.

Differentially expressed genes (DEG) and gene ontology (GO) tests between two *VDR* groups were performed using 'EdgeR' package, which is one of the bioinformatics tools in Bioconductor (<https://www.bioconductor.org/>) ([@bib11]). Pathway enrichment analysis was performed using The Database for Annotation, Visualization and Integrated Discovery (DAVID) (12, 13) and the Gene Set Enrichment Analysis (GSEA) program ([@bib14]). False discovery rate (FDR) correction was used to adjust false-positive rate from multiple testing. All statistical analyses were performed using R 3.2.4. (R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>).

Results
=======

No *VDR* gene single-nucleotide variants were observed in either of the two different mutation calling files. [Figure 1](#fig1){ref-type="fig"} shows the difference in *VDR* mRNA expression between normal and PTC tissues. Both paired and unpaired tests revealed that *VDR* expression was higher in cancer tissue than that in normal tissue (*VDR* expression in 55 normal tissues = 238.971 ± 14.987; in 55 paired cancer tissues = 307.567 ± 26.808; in 501 cancer tissues = 395.276 ± 10.323, mean ± standard error of mean ([s.e.m.]{.smallcaps})). Figure 1*VDR* mRNA expression counts in normal and papillary thyroid carcinoma tissue. (A) Fifty-nine paired normal and cancer tissues. (B) 59 normal vs 501 cancer tissues.

Correlations of *VDR* mRNA expression according to clinicopathologic variables are shown in [Table 1](#tbl1){ref-type="table"}. *VDR* gene expression was higher with statistical significance in classic and tall-cell variant PTC (TCVPTC) than that in follicular variant PTC (FVPTC). *VDR* expression was also significantly upregulated in cases with T4 (tumor stage), N1b (lateral neck node metastasis), high MACIS group and AJCC stage IV. Gender, PTC subtype and N stage were only included in multiple linear regression model. The results also showed an association between *VDR* expression with *BRAF*^V600E^ mutation and recurrence, although the results did not reach statistical significance. Table 1Association between *VDR* mRNA expression and clinicopathologic characteristics of 499 PTC patients by linear regression analysis.**VariableNumberMean ± **s.e.m.***P* value** (univariate)***P* value** (multivariate)Age\<45228390.989 ± 14.2570.669≥45271399.888 ± 14.838GenderM134372.818 ± 17.5390.1790.058F365404.267 ± 12.590SubtypeClassic PTC355408.001 ± 12.670ReferenceReferenceFVPTC^†^101318.546 ± 19.165\<0.0010.009TCVPTC^‡^35494.194 ± 32.0230.0330.059Others8400.611 ± 98.3830.9280.955Size≤2 cm200399.179 ± 15.8650.791\>2 cm299393.576 ± 13.657Lymphovascular invasionNo392393.643 ± 11.8270.688Yes107403.803 ± 21.394T stageT1144377.999 ± 17.633ReferenceT2154382.805 ± 20.7370.858T3184411.481 ± 16.1510.193T417495.216 ± 61.7360.048N stageN0278363.768 ± 12.188ReferenceReferenceN1a120410.893 ± 23.8580.0590.381N1b101466.142 ± 24.895\<0.0010.002M stageM0490396.254 ± 10.4940.759M19372.300 ± 58.740MACISLow345386.576 ± 12.243ReferenceIntermediate78383.270 ± 24.0770.909High76450.675 ± 29.9090.029StageI289379.548 ± 12.535ReferenceII44367.811 ± 35.5990.753III98410.995 ± 26.2920.243IV68461.242 ± 30.2430.009*BRAF* mutationNo258378.672 ± 15.039ReferenceV600E236415.103 ± 14.2990.081Others5370.710 ± 82.3870.939RAS mutationNo446399.870 ± 11.1870.257Yes53361.755 ± 25.071RecurrenceNo459390.370 ± 10.9050.0750.155Yes40458.378 ± 30.682SurvivalAlive485394.442 ± 10.4220.433Dead14443.627 ± 78.110[^2]

To predict recurrence using *VDR* gene expression, we divided continuous *VDR* expression values into binary variables using the tree-based classification and ROC curve. Optimal *VDR* cutoff value obtained was 466.5, with a maximal AUC of 0.624. Based on the cutoff, patients were divided into a low *VDR* group and a high *VDR* group. Low *VDR* group comprised 342 patients and high *VDR* group comprised 157 patients. [Table 2](#tbl2){ref-type="table"} shows the logistic regression results according to binary *VDR* group. Both the univariable and multivariable regression models revealed that high *VDR* group was associated with classic PTC and TCVPTC, advanced AJCC stage (stage IV) and recurrence. Table 2Logistic regression analysis using binary *VDR* mRNA expression (cutoff value = 466.5; AUC = 0.624; low *VDR* group, *n* = 342; high *VDR* group, *n* = 157).**VariablesUnivariateMultivariate**Odds ratio*P* valueOdds ratio*P* valueAge (\<45)≥451.1080.597Gender (M)Female1.0570.801Subtype (classic)FVPTC0.5150.0160.5760.051TCVPTC2.7830.0042.5400.013Others0.6960.6600.7640.747Size (≤2 cm)\>2 cm0.9230.683Lymphovascular invasion (No)Yes1.2630.309T stage (T1)T20.8230.458T31.5070.086T42.8260.046N stage (N0)N1a1.4310.128N1b1.9620.006M stage (M0)M11.0910.903MACIS (low)Intermediate1.1560.592High1.7820.027Stage (I)II0.6490.2750.8070.596III1.3410.2391.0800.772IV2.2440.0031.9250.020*BRAF* mutation (No)V600E1.3490.123Others1.6890.570*RAS* mutation (No)Yes0.5380.080Recurrence (No)Yes2.6250.0042.3290.014Survival (alive)Dead1.2170.729

Total 40 patients showed recurrence after surgery. 21 patients had locoregional recurrence including central and lateral neck nodes, whereas 15 patients had distant recurrence such as bone, lung, etc. There is no information for four patients. In high *VDR* group, 11 patients had locoregional and six patients had distant recurrence (*P* value from Fisher's exact test = 0.002). [Figure 2](#fig2){ref-type="fig"} illustrates recurrence-free survival difference for two *VDR* groups using the Kaplan--Meier estimator. The high *VDR* group showed worse recurrence-free survival than the low *VDR* group (*P* value = 0.018, follow-up duration: median 647 days, range 1--5150 days). There's no statistical significance in overall survival between the two VDR groups. Figure 2Recurrence-free survival in the low and high VDR expression groups.

We performed DEG tests for the low and high VDR groups using EdgeR package. The differential gene expression pattern is shown in [Fig. 3](#fig3){ref-type="fig"}. DEG boundaries were defined as follows: average log CPM (counts per million) \>0 and \| logFC (fold change) \| \>1, and FDR *q*-value \<0.01 (indicated as vertical and horizontal lines in [Fig. 3](#fig3){ref-type="fig"}). A total of 545 genes were highly expressed in high *VDR* group, whereas 91 genes were highly expressed in low *VDR* group. [Table 3](#tbl3){ref-type="table"} lists the top 20 highly expressed DEGs in high *VDR* group. Figure 3MA plot of genes differentially expressed in the low and high VDR expression groups. DEG cutoff consisted of average logCPM (count per million) \>0, \| logFC (fold change) \| \>1 and FDR *q*-value \<0.01. Table 3Top 20 upregulated genes in the high *VDR* group.**Gene IDGene symbollogFClogCPM*P* valueFDR**7421*VDR*1.2824.3122.61E-1494.39E-145165904*XIRP1*4.1000.5243.83E-933.22E-89256076*COL6A5*6.0880.7554.51E-922.53E-8857016*AKR1B10*7.4362.4831.73E-867.27E-831646*AKR1C2*4.0523.3931.47E-784.95E-752877*GPX2*5.0530.2964.00E-771.12E-73146802*SLC47A2*3.1991.0981.38E-593.32E-568038*ADAM12*2.4293.2503.35E-567.05E-538111*GPR68*1.8682.1994.08E-536.24E-50729238*SFTPA2*4.1754.5879.36E-531.31E-4910468*FST*2.8230.5791.06E-511.37E-481281*COL3A1*2.0489.3474.38E-504.91E-476947*TCN1*4.2531.2949.78E-501.03E-461278*COL1A2*1.8949.4902.00E-481.87E-451293*COL6A3*1.7617.4593.02E-482.67E-453909*LAMA3*2.2892.6711.02E-478.32E-4592747*BPIFB1*4.5290.5661.04E-478.32E-4510699*CORIN*1.8360.2841.21E-479.22E-451462*VCAN*2.0825.7406.74E-474.93E-4410631*POSTN*2.1606.8671.07E-467.52E-44

[Supplementary Table 1](http://www.endocrineconnections.org/cgi/content/full/EC-17-0001/DC1) (see section on [supplementary data](#supp1){ref-type="supplementary-material"} given at the end of this article) shows the pathways that are significantly enriched by 545 upregulated DEGs in high *VDR* group, using DAVID. Cellular interaction, autoimmune thyroid disease, immune receptor-related signal pathways, cancer-related chemokine signaling and the JAK-STAT pathway were significantly enriched in high *VDR* group. The GSEA pathway analysis showed similar results: chemokine signaling, immune cell-related pathways, cell adhesion, cellular interactions and the JAK-STAT pathway, all of which are associated with carcinogenesis, were significantly enriched in the high *VDR* group compared to low *VDR* group ([Supplementary Table 2](http://www.endocrineconnections.org/cgi/content/full/EC-17-0001/DC1)). The 'chemokine signaling pathway' that was enriched in both DAVID and GSEA analysis harbors thyroid cancer related 'MAPK signaling pathway' composed with RAS-RAF-MEK-ERK1/2 cascade.

GO analysis conducted with EdgeR also showed increased immune-related biological processes, enrichment of cell membrane components and upregulation of receptor signaling activity in the high *VDR* group. Top 10 enriched gene ontologies in high *VDR* group are listed in [Supplementary Table 3](http://www.endocrineconnections.org/cgi/content/full/EC-17-0001/DC1).

Discussion
==========

Although most thyroid carcinomas have a good prognosis, some types of cancer have intractable features and a significantly unfavorable prognosis. Current prognosis and treatment guidelines are based on clinicopathologic data. Recently, additional information using immunohistochemistry and molecular methods was introduced to improve the sensitivity and specificity of the diagnosis and to predict disease prognosis. Molecular markers such as *BRAF*, *RAS*, RET/PTC rearrangement, RAX8/PPARγ and galectin-3 may be useful for these purposes according to the American Thyroid Association guidelines ([@bib15]).

The hallmark of thyroid cancer, besides aggressive behavior, is a loss of uptake and trapping of radioactive iodine, which means resistance to the best systemic therapy for thyroid cancer. The standard chemotherapy regimens approved for thyroid cancer have poor efficacy and relatively high toxicity compared to their benefit. Therefore, the discovery of alternative therapeutic targets for advanced differentiated thyroid cancer is important ([@bib16]).

Vitamin D receptor is a member of the nuclear hormone receptor superfamily. It binds to DNA at vitamin D3 response elements upon ligand binding to alter the transcription of vitamin D3-responsive genes ([@bib17]). Vitamin D3 appears to exert anticancer activity by decreasing proliferation, promoting re-differentiation, inhibiting angiogenesis and accentuating the effects of standard chemotherapy ([@bib18], [@bib19], [@bib20], [@bib21]).

Clinical interest in the association of vitamin D levels with cancer, and in the potential of vitamin D receptor as a therapeutic target, has dramatically increased in recent years. A correlation between vitamin D and cancer prevention has been shown in breast, prostate and colorectal cancer ([@bib22]). It rises to a consensus conference by the World Health Organization evaluating the evidence associated with vitamin D and cancer ([@bib23]). Observational, preclinical and clinical studies strongly suggest that vitamin D3 deficiency increases the risk of developing multiple malignancies, whereas other studies do not support this hypothesis ([@bib24]). However, several studies suggest that adequate vitamin D3 levels may provide protection against chronic diseases such as cancer and may improve cancer prognosis ([@bib25], [@bib26], [@bib27]). Expression of the *VDR* gene and 25-hydroxyvitamin D3 1-α-hydroxylase, the rate-limiting enzyme in the production of active vitamin D3, has been found in several tissues and tumor types ([@bib28]). Active vitamin D3 is important for regulating differentiation and cell growth in many different organs, and expression of 1a-hydroxylase/VDR is regarded as an important response against tumor progression.

A prior report by Izkhakov and coworkers showed that *VDR* mRNA expression was higher in malignant thyroid tissues than that in normal thyroid tissues, which indicates a possible correlation between *VDR* gene expression and thyroid cancer prognosis ([@bib2]); however, there were no clinicopathological differences between patients with low levels of gene expression and those with high levels of gene expression. Clinckspoor and coworkers reported that lower vitamin D3 metabolism was associated with the progression of thyroid cancer of follicular origin ([@bib29]). Here, we found that overexpression of *VDR* mRNA was correlated with aggressive PTC subtypes -- classic PTC and TCVPTC, lateral neck node metastasis, advanced tumor (T4) and AJCC stage (IV) and worse recurrence-free survival. Our results also showed an association between high *VDR* mRNA and *BRAF*^V600E^ mutant PTC, although did not gain statistical significance. Chemokine signaling pathway enrichment that harbors MAPK signaling cascade derived from two different pathway analyses also suggest that high *VDR* expression may be associated with thyroid cancer progression by enhancing MAPK pathway. Overall, results show that overexpression of *VDR* mRNA is associated with poor prognostic factors in PTC, aggressive subtype, advanced T and AJCC stage, lateral neck node metastasis and worse recurrence-free survival.

One possible explanation for these results is impaired expression of vitamin D receptor on the cell membrane: *VDR* mRNA may be overexpressed in response to decreased vitamin D receptor protein expression in damaged cellular membranes. Another explanation may be genomic discordance between the expression levels of mRNA and the expression of protein. Guo and coworkers reported on the usefulness of mRNA to predict protein expression, but they described that the prediction of protein expression using mRNA was far from perfect ([@bib30]). Because of limitations in our study design, the correlation between *VDR* mRNA expression and vitamin D receptor protein expression could not be clearly assessed in this report. Further study in thyroid cancer is required.

In conclusion, we used public multigenomics data to demonstrate that elevated *VDR* mRNA levels are associated with aggressive PTC subtypes, worse prognostic factors and recurrence-free survival. Further experimental validation should be performed to prove the biologic influence of *VDR* and circulating vitamin D.
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###### Pathways significantly enriched by 545 up-regulated DEGs in the high *VDR* group. Analysis was performed by DAVID

###### 

Click here for additional data file.

###### Top 20 significantly enriched pathways using all 20,531 genes. Analysis was performed using the Gene Set Enrichment Analysis.
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Click here for additional data file.

###### Top 10 enriched gene ontology terms in the high *VDR* group

###### 

Click here for additional data file.
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